Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|New England Journal of Medicine|2016Cited by 768
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|Obstetrical & Gynecological Survey|2016Cited by 373
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension studyJared M. Baeten, Samuel Albert, Thesla Palanee‐Phillips et al.|The Lancet HIV|2021Cited by 111
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, M. Juliana McElrath, Sheetal Kassim et al.|The Journal of Infectious Diseases|2022Cited by 50
Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention TrialElizabeth Montgomery, Sarah T. Roberts, Gonasagrie Nair et al.|AIDS and Behavior|2019Cited by 47